Haemonetics (HAE) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Haemonetics Reports 2nd Quarter Fiscal 2016 Revenue of $220 Million and Adjusted EPS of $0.44, Affirms Recent Full Fiscal Year Guidance
November 4, 2015 6:00 AM ESTBRAINTREE, Mass., Nov. 4, 2015 /PRNewswire/ --
Product Growth Highlights
8% constant currency revenue increases in growth drivers in the second quarter, including:
11% growth in North America plasma disposables revenue 25% growth in TEG® diagnostics disposables revenue 6% growth in Emerging Markets disposables revenue, ex-RussiaHaemonetics Corporation (NYSE: HAE) reported second quarter fiscal 2016 revenue of $219.7 million, down 3%. Revenue was flat with the second quarter of fiscal 2015 in constant currency.Â
The Company reported GAAP net income of $12.9 million and GAAP net earnings per share of $0.25 in the second quarter of... More
